Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Clarus Therapeutics Holdings Inc
Gross Profit
Clarus Therapeutics Holdings Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
Gross Profit
$11.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Clarus Therapeutics Holdings Inc's Gross Profit?
Gross Profit
11.2m
USD
Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Gross Profit amounts to 11.2m USD.